A photo of Margaret Collins.

Margaret H. Collins, MD


  • Staff Pathologist, Division of Pathology
  • Director, GI Pathology
  • Professor, UC Department of Pathology and Laboratory Medicine
  • UC Department of Pediatrics

About

Biography

I belong to a community of researchers at Cincinnati Children’s Hospital Medical Center, plus other institutions here and abroad, who are unwaveringly committed to finding cures for pediatric gastrointestinal (GI) diseases, including eosinophilic gastrointestinal disorders (EGID). This is especially important to me after meeting patients and their caregivers, witnessing the impact that EGID has on their lives and sharing their hope for a Food and Drug Administration (FDA)-approved therapy.

My research strives to improve diagnostic methods for children with GI diseases, such as EGID and inflammatory bowel disease. As a pediatric pathologist at Cincinnati Children’s, I help evaluate the efficacy of various therapies, including biologics, for pediatric patients who have EGID. I also participate in multi-institutional studies of pediatric inflammatory bowel disease.

I helped create the eosinophilic esophagitis histology scoring system (EoEHSS), which systematically evaluates esophageal biopsies obtained for eosinophilic esophagitis, the most common form of EGID. Some of the features evaluated correlate with symptoms and potentially provide new therapeutic endpoints.

Beginning in 2011, U.S. News & World Report named me one of the Top Doctors in Pathology. In 2020, I received the American Academy of Asthma, Allergy and Immunology (AAAAI) and American Partnership for Eosinophilic Disorders (APFED) award for the best EGID abstract at the AAAAI annual meeting.

BS: Fordham University, NY, 1972.

MD: Georgetown University, Washington, D.C., 1977.

Residency: Pathology, New York Hospital, NY, 1977-80; Pathology, Columbia-Presbyterian Medical Center, NY, 1980-83.

Fellowship: Research, New York Lung Association, Columbia-Presbyterian Medical Center, N.Y., 1983-85; Research, American Lung Association, Columbia-Presbyterian Medical Center, NY, 1985-87.

Certification: Pathology, 1981; Pediatric Pathology, 1991.

Interests

Pediatric gastrointestinal pathology; eosinophilic gastrointestinal diseases; biopsy analyses; primary study endpoints; novel therapies to treat eosinophilic esophagitis in children; disorders of bowel immunity; bowel motility disorders

Services and Specialties

Colorectal Disorders, Pathology, Eosinophilic Disorders

Research Areas

Pathology, Eosinophilic Disorders

Publications

Ascending to New Heights for Novel Therapeutics for Eosinophilic Esophagitis. Hirano, I; Dellon, ES; Falk, GW; Gonsalves, NP; Furuta, GT; Bredenoord, AJ; Straumann, A; Schoepfer, A; Chang, JW; Peterson, K; et al. Gastroenterology. 2024; 166:1-10.

Breakthroughs in understanding and treating eosinophilic gastrointestinal diseases presented at the CEGIR/TIGERs Symposium at the 2022 American Academy of Allergy, Asthma & Immunology Meeting. Chehade, M; Wright, BL; Atkins, D; Aceves, SS; Ackerman, SJ; Assa'ad, AH; Bauer, M; Collins, MH; Commins, SP; Davis, CM; et al. Journal of Allergy and Clinical Immunology. 2023; 152:1382-1393.

Pooled Phase 2 and 3 Efficacy and Safety Data on Budesonide Oral Suspension in Adolescents with Eosinophilic Esophagitis. Mukkada, VA; Gupta, SK; Gold, BD; Dellon, ES; Collins, MH; Katzka, DA; Falk, GW; Williams, J; Zhang, W; Boules, M; et al. Journal of Pediatric Gastroenterology and Nutrition. 2023; 77:760-768.

Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Rothenberg, ME; Dellon, ES; Collins, MH; Hirano, I; Chehade, M; Bredenoord, AJ; Lucendo, AJ; Spergel, JM; Sun, X; Hamilton, JD; et al. The Lancet Gastroenterology and Hepatology. 2023; 8:990-1004.

Esophageal Epithelium and Lamina Propria Are Unevenly Involved in Eosinophilic Esophagitis. Hiremath, G; Sun, L; Collins, MH; Bonis, PA; Arva, NC; Capocelli, KE; Chehade, M; Davis, CM; Falk, GW; Gonsalves, N; et al. Clinical Gastroenterology and Hepatology. 2023; 21:2807-2816.e3.

Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial. Kliewer, KL; Murray-Petzold, C; Collins, MH; Abonia, JP; Bolton, SM; DiTommaso, LA; Martin, LJ; Zhang, X; Mukkada, VA; Putnam, PE; et al. The Lancet Gastroenterology and Hepatology. 2023; 8:803-815.

Eosinophilic Esophagitis Histologic Scoring System: Correlation with Histologic, Endoscopic, and Symptomatic Disease and Clinical Use. Alexander, RG; Ravi, K; Collins, MH; Lavey, CJ; Snyder, DL; Lennon, RJ; Kassmeyer, BA; Katzka, DA; Alexander, JA. Digestive Diseases and Sciences. 2023; 68:3573-3583.

Monitoring Patients With Eosinophilic Esophagitis in Routine Clinical Practice - International Expert Recommendations. Arnim, UV; Biedermann, L; Aceves, SS; Bonis, PA; Collins, MH; Dellon, ES; Furuta, GT; Gonsalves, N; Gupta, S; Hirano, I; et al. Clinical Gastroenterology and Hepatology. 2023; 21:2526-2533.

Harnessing Digital Pathology And Causal Learning To Improve Eosinophilic Esophagitis Dietary Treatment Assignment. Aknin, E; Larey, A; Caldwell, JM; Collins, MH; Rothenberg, ME; Savir, Y. (2023) Institute of Electrical and Electronics Engineers (IEEE). 00:1-8.

262. DUPILUMAB REDUCED EOSINOPHIL COUNTS AND IMPROVED HISTOLOGY GRADE/STAGE SCORES IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: LIBERTY EOE TREET RESULTS. Collins, M; Dellon, ES; Pela, T; Aceves, SS; Lucendo, AJ; Spergel, JM; Sun, X; Khodzhayev, A; Radwan, A; Jacob-Nara, J. Gullet. 2023; 36:doad052.103.

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey

4.6
Overall Patient Rating